Regeneron Pharmaceuticals announced positive three-year results from an extension study of EYLEA HD (aflibercept) Injection 8 mg for treating wet age-related macular degeneration (wAMD). The findings, ...

TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...

Regeneron Pharmaceuticals has announced the U.S. FDA's acceptance for Priority Review of the supplemental Biologics License Application for EYLEA HD (aflibercept) Injection 8 mg, which, if approved, ...

TARRYTOWN, N.Y., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual ...

May 23 (Reuters) - German drugmaker Bayer (BAYGn.DE), opens new tab on Friday won an endorsement by the European Medicines Agency to extend the intervals between shots of its anti-blindness treatment ...

Add Yahoo as a preferred source to see more of our stories on Google. Feb 17 (Reuters) - Ocular Therapeutix said on Tuesday its experimental eye disease drug was more effective in helping patients ...

Please provide your email address to receive an email when new articles are posted on . FYB203/Ahzantive was comparable to Eylea for the treatment of neovascular age-related macular degeneration. A ...

The Retina Group of New York announced the availability of Eylea, the latest in a series of anti-VEGF medications for all patients with the wet form of age-related macular degeneration (AMD). The ...

On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ: REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following ...

The MHRA has granted marketing authorisation for Eylea ® (aflibercept 8 mg) for the treatment of patients with macular oedema following retinal vein occlusion (RVO) including branch, central and ...